Geode Capital Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-37,934
| Closed | -$48.2K | – | 4796 |
|
|
2023
Q3 | $48.2K | Sell |
37,934
-349,412
| -90% | -$305K | ﹤0.01% | 4428 |
|
|
2023
Q2 | $126K | Hold |
387,346
| – | – | ﹤0.01% | 4244 |
|
|
2023
Q1 | $167K | Hold |
387,346
| – | – | ﹤0.01% | 4133 |
|
|
2022
Q4 | $205K | Sell |
387,346
-25,055
| -6% | -$15.9K | ﹤0.01% | 4083 |
|
|
2022
Q3 | $301K | Hold |
412,401
| – | – | ﹤0.01% | 3984 |
|
|
2022
Q2 | $470K | Sell |
412,401
-6,166
| -1% | -$7.85K | ﹤0.01% | 3802 |
|
|
2022
Q1 | $858K | Buy |
418,567
+63,058
| +18% | +$150K | ﹤0.01% | 3684 |
|
|
2021
Q4 | $1.02M | Buy |
355,509
+5,737
| +2% | +$21.2K | ﹤0.01% | 3712 |
|
|
2021
Q3 | $1.48M | Buy |
349,772
+26,658
| +8% | +$119K | ﹤0.01% | 3493 |
|
|
2021
Q2 | $1.71M | Buy |
323,114
+84,191
| +35% | +$405K | ﹤0.01% | 3334 |
|
|
2021
Q1 | $1.11M | Buy |
238,923
+70,113
| +42% | +$318K | ﹤0.01% | 3510 |
|
|
2020
Q4 | $557K | Buy |
168,810
+3,901
| +2% | +$14.8K | ﹤0.01% | 3557 |
|
|
2020
Q3 | $545K | Sell |
164,909
-2,466
| -1% | -$9.06K | ﹤0.01% | 3403 |
|
|
2020
Q2 | $564K | Sell |
167,375
-132,039
| -44% | -$624K | ﹤0.01% | 3328 |
|
|
2020
Q1 | $1.15M | Buy |
299,414
+19,915
| +7% | +$92.5K | ﹤0.01% | 2960 |
|
|
2019
Q4 | $1.69M | Buy |
279,499
+4,749
| +2% | +$32.5K | ﹤0.01% | 3084 |
|
|
2019
Q3 | $2.08M | Buy |
274,750
+16,641
| +6% | +$188K | ﹤0.01% | 2923 |
|
|
2019
Q2 | $3.5M | Buy |
258,109
+154,634
| +149% | +$1.79M | ﹤0.01% | 2618 |
|
|
2019
Q1 | $560K | Buy |
103,475
+1,828
| +2% | +$8.89K | ﹤0.01% | 3399 |
|
|
2018
Q4 | $301K | Sell |
101,647
-853
| -0.8% | -$4.67K | ﹤0.01% | 3554 |
|
|
2018
Q3 | $835K | Buy |
102,500
+26,713
| +35% | +$205K | ﹤0.01% | 3294 |
|
|
2018
Q2 | $738K | Sell |
75,787
-25,515
| -25% | -$262K | ﹤0.01% | 3300 |
|
|
2018
Q1 | $880K | Buy |
101,302
+1,095
| +1% | +$11.8K | ﹤0.01% | 3182 |
|
|
2017
Q4 | $1.25M | Buy |
100,207
+2,625
| +3% | +$30.1K | ﹤0.01% | 3008 |
|
|
2017
Q3 | $815K | Buy |
97,582
+1,437
| +1% | +$15.2K | ﹤0.01% | 3191 |
|
|
2017
Q2 | $1.63M | Buy |
96,145
+20,130
| +26% | +$400K | ﹤0.01% | 2848 |
|
|
2017
Q1 | $1.53M | Buy |
76,015
+27,789
| +58% | +$552K | ﹤0.01% | 2796 |
|
|
2016
Q4 | $751K | Buy |
48,226
+1,833
| +4% | +$24.7K | ﹤0.01% | 3120 |
|
|
2016
Q3 | $605K | Buy |
46,393
+34,517
| +291% | +$328K | ﹤0.01% | 3178 |
|
|
2016
Q2 | $81K | Sell |
11,876
-2,953
| -20% | -$24.7K | ﹤0.01% | 3845 |
|
|
2016
Q1 | $140 | Sell |
14,829
-25
| -0.2% | -$202 | ﹤0.01% | 3737 |
|
|
2015
Q4 | $149K | Buy |
14,854
+1,545
| +12% | +$20.4K | ﹤0.01% | 3782 |
|
|
2015
Q3 | $190K | Buy |
+13,309
| New | +$327K | ﹤0.01% | 3699 |
|
Geode Capital Management's ZYNE Position: Q4 2023 in Review
Geode Capital Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2023, closing a stake of 37,934 shares — an estimated $48.2K sold.
Geode Capital Management first reported a position in ZYNE in Q3 2015 and held it in 33 quarters. The position peaked at $3.5M in Q2 2019. 0 funds tracked by Wall St. Rank hold ZYNE as of Q4 2023.
- Geode Capital Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2023 after selling out during the quarter.
- Geode Capital Management sold 37,934 Zynerba Pharmaceuticals, Inc shares in Q4 2023, an estimated $48.2K.
- Geode Capital Management first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2015 and held it in 33 quarters.
- Geode Capital Management's Zynerba Pharmaceuticals, Inc position peaked at $3.5M in Q2 2019.
- 0 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2023.
Based on Geode Capital Management's 13F filing for Q4 2023, filed 13 Feb 2024.